Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews · Gut

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 2 · 28.6%Moderate 2 · 28.6%High 2 · 28.6%

Overall survival · people with advanced gastric cancer

S‐1 showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (high certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.91 [0.83, 1]
4 studies · 1793 participants
High

Tumour response · people with advanced gastric cancer

It is very uncertain whether S‐1 changes tumour response compared with 5‐FU‐containing regimens (very low certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
OR 1.73 [1.01, 2.94]
7 studies · 1753 participants
Very low

Progression‐free survival · people with advanced gastric cancer

S‐1 showed no clear difference in progression‐free survival compared with 5‐FU‐containing regimens (low certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.85 [0.7, 1.04]
4 studies · 1942 participants
Low

Time‐to treatment failure · people with advanced gastric cancer

S‐1 showed no clear difference in time‐to treatment failure compared with 5‐FU‐containing regimens (low certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.88 [0.76, 1.01]
5 studies · 1818 participants
Low

Treatment‐related deaths · people with advanced gastric cancer

S‐1 showed no clear difference in treatment‐related deaths compared with 5‐FU‐containing regimens (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
OR 0.56 [0.3, 1.06]
4 studies · 1962 participants
Moderate

Treatment discontinuation due to toxicity · people with advanced gastric cancer

S‐1 showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (high certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
OR 0.85 [0.63, 1.13]
3 studies · 1726 participants
High

Quality of life (2 weeks‐12 months) · people with inflammatory bowel disease

1 finding from 1 review

Patient education interventions for the management of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1364 participants
Moderate